Bio-Techne Corp beat EPS estimates 69% of the time across 16 reported quarters (11 beats, 5 misses), averaging +3.4% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q4 FY26 | $0.46 | $0.49 | +6.5% | Beat | |
| Q3 FY26 | $0.48 | $0.48 | +0.0% | Beat | Q3 FY26 call · transcript |
| Q2 FY26 | $0.34 | $0.39 | +14.7% | Beat | Q2 FY26 call · transcript |
| Q1 FY26 | $0.36 | $0.36 | +0.0% | Beat | Q1 FY26 call · transcript |
| Q4 FY25 | $0.46 | $0.51 | +10.9% | Beat | Q4 FY25 call · transcript |
| Q3 FY25 | $0.45 | $0.50 | +11.1% | Beat | Q3 FY25 call · transcript |
| Q2 FY25 | $0.33 | $0.35 | +6.1% | Beat | |
| Q1 FY25 | $0.34 | $0.37 | +8.8% | Beat | |
| Q4 FY24 | $0.44 | $0.49 | +11.4% | Beat | |
| Q3 FY24 | $0.40 | $0.44 | +10.0% | Beat | |
| Q2 FY24 | $0.36 | $0.33 | -8.3% | Miss | |
| Q1 FY24 | $0.39 | $0.35 | -10.3% | Miss |
Back to TECH overview · TECH holders · TECH KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.